AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00418522
Drug: Inhaled Insulin (Exubera)
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Trial: NCT01387425
Drug: placebo tablet is made of lactose
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo at a dose of 1 mg twice for 12 week
Trial: NCT02695719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone placebo-matching capsules
Trial: NCT04357613
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 800mg/d during 14days
Trial: NCT04109313
Drug: LOU064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
Trial: NCT00006108
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01279252
Drug: metronidazole, clarithromycin, ciprofloxacin and lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02936687
Drug: ET-1 Inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
Trial: NCT02936687
Drug: NOS Inhibition Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be infused at the same rate and quantity as the corresponding drug visit.
Trial: NCT02936687
Drug: ET-1 Inhibition Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
Trial: NCT04691375
Drug: PY314
RxNorm normalized name: Pyridoxine
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of PY314 as a single agent given in a standard 3+3 design.
Trial: NCT01552967
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles.
Trial: NCT02231424
Drug: Drug: Berodual®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04429334
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01389934
Drug: levo-bupicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
Trial: NCT01389934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women of this group be infused saline 2 ml / h for 48h.
Trial: NCT01173913
Drug: ModraDoc001 10mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-daily administration. One cycle will last 7 days
Trial: NCT01173913
Drug: ModraDoc003 10mg tablets and ModraDoc004 10/50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
Trial: NCT01173913
Drug: ModraDoc006 10 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-daily administration. One cycle will last 7 days
Trial: NCT00567736
Drug: Disci/Rhus toxicodendron comp.®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Trial: NCT00567736
Drug: placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Trial: NCT00811434
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml sugar water/kg day for three months
Trial: NCT00289003
Drug: Soluble beta-1,3/1,6-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00353652
Drug: Study #1: spironolactone (SP), titrated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
Trial: NCT00353652
Drug: Study# 2 chlorthalidone (CTD), fixed dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
Trial: NCT00353652
Drug: Study# 2 spironolactone (SP), fixed dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
Trial: NCT00353652
Drug: Study# 2 irbsesartan (IR), fixed dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
Trial: NCT01784666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Trial: NCT04284514
Drug: AKB-9778 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKB-9778 Ophthalmic Solution
Trial: NCT04284514
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched vehicle-control
Trial: NCT04626752
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/㎡ for D-3 and D-2
Trial: NCT03026907
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
Trial: NCT03026907
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
Trial: NCT00431275
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-675,206 15 mg/kg iv single dose on Day 1
Trial: NCT00004175
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004175
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02225665
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: - IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
Trial: NCT04595916
Drug: Polyene phosphatidylcholine injection 930 mg QD
RxNorm normalized name: dimyristoyl phosphatidylcholine
DrugBank: DL-dimyristoylphosphatidylcholine (DB11283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
Trial: NCT05378919
Drug: Fluorouracil/folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
Trial: NCT05378919
Drug: Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
Trial: NCT04247984
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
Trial: NCT04537767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00536601
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02502734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Trial: NCT02070692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day course of placebo during an episode of irregular vaginal bleeding
Trial: NCT04487743
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Trial: NCT03357081
Drug: CEUS or Contrast enhanced Ultrasound
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
Trial: NCT00000476
Drug: digitalis
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01638650
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in accordance with current clinical HIV treatment guidelines
Trial: NCT00004997
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02581878
Drug: BAY1862864
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Trial: NCT04392557
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin / Alogliptin/ Pioglitazone
Trial: NCT04131231
Drug: microparticles packaging methotrexate (MPs-MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50ml, intrapleural infusion, day5,6,7,8
Trial: NCT03138681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo is given intravenously twice a day for 14 days
Trial: NCT03138681
Drug: ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP (100mg) is given intravenously twice a day for 14 days
Trial: NCT03560687
Drug: Sucrosomial Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CardioSideral 2 caps per day
Trial: NCT00005622
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
Trial: NCT01355159
Drug: Folic Acid 4 mg
RxNorm normalized name: multivit,min17/iron/folic acid 4 mg-0.3 mg ORAL TABLET,DISINTEGRATING
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
Trial: NCT01355159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo x 4 tablets will be taken daily by oral administration.
Trial: NCT01534637
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01534637
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01640873
Drug: MK-8655
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
Trial: NCT01640873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
Trial: NCT00720226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill daily
Trial: NCT02303314
Drug: Trigonella Foenum-graecum Seed Extract
RxNorm normalized name: Trigonella foenum-graecum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02303314
Drug: Drug: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01020799
Drug: AZD7268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg, oral, twice daily (BID)
Trial: NCT01020799
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match AZD7268
Trial: NCT01020799
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match encapsulated escitalopram
Trial: NCT00962988
Drug: Cost-Free Pharmacotherapy Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months.
Trial: NCT00662259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, bid, p.o. for 28 +/- 2 days.
Trial: NCT00792727
Drug: ketoprofen Patch
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 topical patches applied once daily for 28 days
Trial: NCT03597867
Drug: Dicloftil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of drug 3 days prior to surgery
Trial: NCT00568074
Drug: Glurenorm®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568074
Drug: Glucobay®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01602016
Drug: Folinic Acid and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
Trial: NCT01949116
Drug: LDMTX
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly
Trial: NCT01949116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly
Trial: NCT03507413
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
Trial: NCT00190242
Drug: group1
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix at 1440IU was administrated à weeks S0, S4 and S24
Trial: NCT00190242
Drug: group2
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
Trial: NCT03597867
Drug: Indom
RxNorm normalized name: Indomax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of drug 3 days prior to surgery
Trial: NCT02694874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo control
Trial: NCT01824901
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01148758
Drug: RO5323441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cohorts receiving multiple doses iv
Trial: NCT03130114
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
Trial: NCT01764243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02397005
Drug: ZL-2102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
Trial: NCT02397005
Drug: Placebo matching ZL-2102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03135652
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
Trial: NCT02006537
Drug: GSK2256294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
Trial: NCT02593227
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion over 1 hour
Trial: NCT02631876
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Trial: NCT00216645
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00489281
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
Trial: NCT02714231
Drug: diclofenac sodium (cataflam)
RxNorm normalized name: diclofenac Oral Tablet [Cataflam]
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
Trial: NCT00286819
Drug: the FEC75 and 95 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B
Trial: NCT00536484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.